id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-346307-xejs2va1	Rysz, Susanne	Treatment with angiotensin II in COVID-19 patients may not be beneficial	2020-09-04		.txt	text/plain	815	50	53	The authors refer to the ATHOSIII trial as support for the use of ANGII in catecholamine-resistant vasodilatory shock despite the known concern for thrombotic and infectious complications associated with ANGII [2] . In addition, the authors suggest to use ANGII in COVID-19 patients recently exposed to angiotensin-converting enzyme inhibitors. In a recent COVID-19 case series, ANGII levels were markedly elevated and linearly associated with viral load and lung injury [4] . Moreover, in a prepublished report currently under journal review, infusion of ANGII in a porcine model rapidly (within hours) induced a clinical syndrome closely reflecting the one seen in COVID-19 patients, including histological changes in the lungs with severe thickening of the alveolar walls, possible hyaline membranes, and clotting of vessels, as previously reported in the human COVID-19 phenotype [5] . Angiotensin II infusion in COVID-19-associated vasodilatory shock: a case series Treatment with angiotensin II in COVID-19 patients may not be beneficial.	./cache/cord-346307-xejs2va1.txt	./txt/cord-346307-xejs2va1.txt